Other Events ·
Fresenius Medical Care exits peritoneal dialysis business, incurs €110M one-time costs from strategy refinements
FMCQFFresenius Medical Care AG
Fresenius Medical Care announced refinements to its China commercial strategy, focusing on a localized portfolio and discontinuing production of the 4008A hemodialysis system while exiting its peritoneal dialysis business. The company appointed Rex Liu as market General Manager to strengthen local leadership. These actions are expected to result in one-time costs of approximately €110 million, primarily for impairment charges and scrappage, recognized as a special item in Q3 2026. The adjustment is not expected to meaningfully impact future revenue outlooks for the China business. Fresenius Medical Care operates in the healthcare industry, providing dialysis products and services for patients with renal diseases.